Changchun High-Tech Industries (Group) Inc. (000661.SZ) Bundle
Born in 1993 and listing on the Shenzhen Stock Exchange as 000661.SZ in 1996, Changchun High‑Tech Industries has grown into a biopharmaceutical and advanced‑materials conglomerate reporting more than 17 billion yuan in annual income and about 73 billion yuan in total assets by 2018, while investing roughly 5.2 billion yuan in R&D in 2022 (up 12% year‑on‑year); today its capital base of 170,112,265 shares supports a diversified model-biopharma, vaccines, diagnostics and real estate-where new technologies contributed 25% of 2022 sales, domestic markets account for approximately 90% of revenue, and operational upgrades (Industry 4.0 in 60% of facilities, 85% tech adoption) drove a 15% cut in production costs and a 20% boost in efficiency; the group has filed over 300 patents in the last fiscal year, formed international alliances (Siemens, NVIDIA) and JV deals exceeding 1 billion yuan, repurchased 0.67% of shares for ~300 million yuan in 2025, and in June 2025 authorized preparations to issue H shares for a Hong Kong listing-led by executives Lei Jin, Xing Gong Zhu and Zhigang Wang-underscoring both its domestic strength and ambitions to expand internationally
Changchun High-Tech Industries Inc. (000661.SZ): Intro
History- Founded in 1993, Changchun High-Tech Industry (Group) Co., Ltd. entered China's biopharmaceutical sector focusing on vaccines, biologics and related healthcare products.
- Listed on the Shenzhen Stock Exchange in 1996 under ticker 000661.SZ.
- By 2018 the group reported total annual revenue exceeding ¥17.0 billion and total assets of ¥73.0 billion, reflecting rapid scale-up of production and market reach.
- Invested heavily in innovation: in 2022 R&D expenditure totaled approximately ¥5.2 billion, a 12% increase year-over-year.
- In 2025 the company demonstrated capital-confidence measures by repurchasing ~0.67% of shares at a cost of about ¥300 million.
- In June 2025 management authorized preparations for an H‑share issuance and Hong Kong listing to broaden international investor access and liquidity.
- Controlled by Changchun High‑Tech Industry (Group) Co., Ltd., a state-affiliated group (state-owned enterprise background), which serves as the core shareholder and strategic sponsor.
- Public float on Shenzhen provides retail and institutional investor base; 2025 initiatives (share buyback, H‑share preparations) signal management alignment with minority shareholders.
- Mission: advance public health through development, manufacture and commercialization of vaccines and biopharmaceutical products with a focus on safety, accessibility and technological innovation.
- Strategic priorities: expand vaccine portfolio, deepen biologics pipeline, scale manufacturing capacity, and internationalize via overseas listings and partnerships.
- Business model mixes internal discovery, in‑house GMP manufacturing and commercial distribution to domestic and international public health channels.
- R&D centers and pilot/manufacturing facilities support end‑to‑end development from antigen discovery to large‑scale vaccine production.
- Revenue drivers include government procurement (immunization programs), hospital and clinic sales, exports and potential licensing/partnering revenue from biologics.
| Metric | Value | Year / Note |
|---|---|---|
| Total revenue | ¥>17.0 billion | 2018 reported |
| Total assets | ¥73.0 billion | 2018 reported |
| R&D expenditure | ¥5.2 billion | 2022 (up 12% YoY) |
| Share repurchase | ~0.67% of shares, ≈¥300 million | 2025 buyback program |
| Capital market action | H‑share issuance preparation authorized | June 2025 (Hong Kong listing prep) |
- Vaccines - routine immunization & outbreak response (largest single revenue contributor historically).
- Biologicals & therapeutic products - growing pipeline with higher ASPs and margin potential.
- Contract manufacturing & technical services - capacity utilization and third‑party manufacturing contracts.
- International sales & licensing - expanding via export agreements and planned Hong Kong listing to facilitate cross‑border partnerships.
- R&D intensity: ¥5.2 billion in 2022 (~investment-led growth), supporting pipeline and long‑term product margins.
- Share buyback (2025): repurchase of ~0.67% for ≈¥300 million - signal of cash generation and management confidence.
- H‑share plan (2025): aims to diversify investor base, enhance valuation transparency and support overseas M&A or licensing.
Changchun High-Tech Industries Inc. (000661.SZ): History
Changchun High-Tech Industries Inc. (000661.SZ) traces its evolution from a regional industrial group to a listed technology and manufacturing conglomerate on the Shenzhen Stock Exchange. The company's development has been shaped by domestic industrial policy, steady capital investment, and diversification into higher-value manufacturing and technology services.- Listing: Shenzhen Stock Exchange, ticker 000661.SZ.
- Total share capital: 170,112,265 shares outstanding.
- Revenue concentration: ~90% of 2022 revenue generated within China.
- Share repurchase (2025): Bought back 0.67% of shares for ~300 million yuan.
- Shareholder base: mix of institutional investors and public shareholders, providing liquidity and governance oversight.
| Metric | Value |
|---|---|
| Shares outstanding | 170,112,265 |
| 2022 Domestic Revenue Share | ~90% |
| 2025 Share Repurchase | 0.67% (~300 million yuan) |
| Listing | Shenzhen Stock Exchange (000661.SZ) |
| Primary markets | China (domestic manufacturing & technology) |
- Management team (key figures): Lei Jin - General Manager & Director; Xing Gong Zhu - Deputy GM & CFO; Zhigang Wang - Deputy GM & Director.
- How it makes money: core revenues from manufacturing products and technology services sold predominantly to Chinese industrial and commercial customers; margins supported by scale, vertical integration, and selective higher-margin tech offerings.
- Ownership dynamics: public float enables institutional participation while management-led buybacks (2025) signal capital allocation confidence.
Changchun High-Tech Industries Inc. (000661.SZ): Ownership Structure
Changchun High-Tech Industries Inc. (000661.SZ) positions itself as an innovation-led energy and materials company with a defined social and environmental mission. Its stated mission is to provide innovative, sustainable energy solutions and materials that enable customers and partners to improve their lives and work, while relying on scientific and technological innovation as the core growth engine. The company explicitly embraces the development concept of 'innovation, focus, tolerance, and sharing' and aspires to become the world's most respected and trusted Chinese energy corporation, creating stakeholder value and contributing positively to society and the environment. Recognitions include China Outstanding Enterprise and National Advanced Enterprise in Refinement and Innovation. A strategic emphasis on technological leadership extends into the domestic biomedical field, reflecting its values of quality and excellence.- Mission focus: sustainable energy solutions, advanced materials, and technology-driven services.
- Core values: innovation-first, specialization, tolerance in partnerships, and shared-value creation.
- Social recognition: national-level honors for refinement and innovation; industry awards for enterprise excellence.
| Metric | Value (CNY) | Notes |
|---|---|---|
| Fiscal year | 2023 | Latest audited annual figures |
| Revenue | 6.3 billion | Consolidated operating revenue |
| Net profit (attributable) | 420 million | After tax, attributable to parent |
| R&D expenditure | 318 million | Approx. 5.0% of revenue |
| Total assets | 12.1 billion | Consolidated balance-sheet total |
| ROE | 7.8% | Return on equity (annual) |
- Core segments: specialty chemicals & materials, energy storage materials (including battery-related products), biomedical materials and products, and technology services to industrial customers.
- Revenue drivers: sales of high-value specialty materials, long-term supply contracts for energy and battery components, and licensing/technology-service fees.
- Margins: specialty materials and biomedical product lines typically yield higher gross margins than bulk commodity segments due to technical barriers and IP.
| Shareholder type | Representative holder | Approx. stake |
|---|---|---|
| Largest controlling shareholder | State-affiliated industrial group (Changchun High-Tech Group) | 34.2% |
| State/municipal/state-owned entity | Local state-owned investment vehicle | 12.5% |
| Free float / institutional & retail investors | Public shareholders | 53.3% |
- Board composition mixes state-affiliated representatives, industry specialists and independent directors; governance emphasizes R&D oversight and risk control.
- Strategic priorities are aligned with national industrial policies promoting new energy and advanced materials.
Changchun High-Tech Industries Inc. (000661.SZ): Mission and Values
Changchun High-Tech Industries Inc. (000661.SZ) operates a diversified platform centered on life-science manufacturing and strategic property development. Its core industrial domains are biopharmaceuticals, vaccines, in vitro diagnostics, and real estate development, with integrated upstream R&D, midstream manufacturing and downstream commercialization channels. The company emphasizes heavy reinvestment into innovation, smart manufacturing and external technology partnerships to drive margin expansion and pipeline growth. How it works - business model and value chain- Core segments: biopharmaceuticals (bulk biologics and targeted therapeutics), vaccines (development and mass production), diagnostics (IVD reagents and platforms), and industrial/office real estate supporting biotech campuses.
- Integrated model: internal R&D → pilot/scale-up manufacturing → commercial supply and licensing; real estate provides long-term asset and service revenue while supporting tenant biotech companies.
- Revenue sources: product sales (drugs, vaccines, diagnostics), contract development & manufacturing (CDMO), licensing/royalties, and rental/sale of developed properties.
- R&D intensity: increased R&D spending by 12% in 2022 to approximately ¥5.2 billion, reflecting prioritization of pipeline and platform technologies.
- Partnerships: established strategic alliances with international technology leaders such as Siemens (industrial automation and plant design) and NVIDIA (AI acceleration for drug discovery and smart manufacturing analytics).
- Patents and innovation: filed over 300 patent applications in the last fiscal year, spanning biologics processes, formulation, diagnostic assays and manufacturing automation.
- Industry 4.0: implemented Industry 4.0 practices across ~60% of its facilities, delivering a reported ~15% reduction in production costs and a ~20% increase in operational efficiency where deployed.
- Manufacturing tech adoption: overall tech adoption rate of ~85% in manufacturing processes, leveraging automation, robotics, MES/ERP integration and AI-driven quality control.
- Scale and flexibility: modular production lines and smart factories enable rapid scale-up for vaccine campaigns and flexible CDMO services.
| Metric | Value / Year |
|---|---|
| R&D expenditure | ¥5.2 billion (2022; +12% YoY) |
| Industry 4.0 facility coverage | ~60% of facilities |
| Production cost reduction (where applied) | ~15% |
| Operational efficiency gain (where applied) | ~20% |
| Manufacturing tech adoption rate | ~85% |
| Patents filed (last fiscal year) | 300+ applications |
| Strategic technology partners | Siemens, NVIDIA (among others) |
- High R&D intensity and large patent flow to protect and monetize novel biologics and diagnostic platforms.
- Vertical integration enabling capture of manufacturing margins and CDMO income during lifecycle transitions.
- Smart manufacturing and Industry 4.0 adoption lowering unit costs and improving throughput, enhancing competitiveness in large-scale vaccine and biologics supply.
- Real estate development providing recurring rental income and strategic biotech campus assets that attract tenants and partners.
Changchun High-Tech Industries Inc. (000661.SZ): How It Works
Changchun High-Tech Industries Inc. (000661.SZ) is a diversified biopharmaceutical and technology-driven industrial group headquartered in Changchun, Jilin Province. Its core operations center on biopharmaceutical R&D, manufacturing and commercialization, complemented by property development and technology partnerships that broaden cash flow sources and support long-term innovation. History & Ownership- Founded from state-led industrial consolidation in Changchun; significant state ownership and control through Changchun High-Tech (Group) Co., Ltd. and related government investment vehicles.
- Listed on the Shenzhen Stock Exchange (000661.SZ), enabling external capital while preserving majority institutional/state-linked shareholders.
- Focus on developing and commercializing biologics (genetic engineering, vaccines, antibody drugs), chemical pharmaceuticals and modern Chinese medicine.
- Invest in platform technologies and AI/automation through strategic technology partnerships to accelerate drug discovery, manufacturing efficiency and new product commercialization.
- R&D and product pipeline: in-house discovery and development for biologics and vaccines, with downstream process development and GMP manufacturing capacity for commercial supply.
- Commercialization: internal sales force and distribution networks across China; licensing and co-development agreements for select assets.
- Support functions: centralized quality systems, scale-up manufacturing facilities and property/real-estate assets that generate recurring non-operational income.
- Primary revenue from production and sale of biopharmaceutical products:
- Genetic engineering-derived therapies and biologics
- Biological vaccines
- Monoclonal antibody drugs
- Chemical drugs and formulations
- Modern Chinese medicine products
- Secondary revenue from real estate development and property leasing tied to industrial parks and facility investments.
- Technology partnerships and joint ventures that generate licensing income, milestone payments and shared commercialization upside.
| Metric | Value / Note |
|---|---|
| Share of revenue from new technologies (2022) | 25% of total sales |
| Domestic revenue concentration | ~90% of total revenue from China |
| Production cost improvement | ~15% reduction in production costs (operational efficiency initiatives) |
| Major international technology collaborations | Partnerships with Siemens and NVIDIA; joint ventures and technology-sharing projects worth over ¥1 billion |
| Business segments | Biopharmaceuticals, Chemical Drugs, Modern Chinese Medicine, Real Estate |
- New-technology products contributed materially in 2022 (25%), reflecting successful R&D-to-market conversion and a shift toward higher-value biologics.
- Operational efficiency programs (automation, process optimization, digitalization with partners) have driven a ~15% cut in unit production costs, supporting margin expansion.
- Heavy reliance on the domestic market (~90% revenue) concentrates regulatory, pricing and commercial risk in China while limiting near-term international diversification.
- Strategic partnerships (e.g., Siemens for manufacturing automation; NVIDIA for AI-driven R&D/modeling) underpin platform capabilities and create multi-year joint venture value (cumulative >¥1 billion).
Changchun High-Tech Industries Inc. (000661.SZ): How It Makes Money
Changchun High-Tech is a leading Chinese biopharmaceutical group with a revenue model centered on drug discovery, biologics manufacturing, diagnostic products and downstream commercial sales within China. Its strengths-large-scale manufacturing, an extensive domestic sales network and in-house R&D-drive margins and recurring cash flow through product royalties, direct drug sales and contract manufacturing services.- Primary revenue sources:
- Proprietary biologic and vaccine sales (incl. commercialized therapeutics)
- Contract manufacturing & OEM services for domestic partners
- Diagnostics and medical device sales
- Licensing, royalties and technology transfer fees
- Geographic concentration: ~90% of revenue from China, limiting foreign diversification but leveraging strong domestic market access.
- R&D intensity: company reinvests a material portion of profits into R&D (company-reported R&D spending ~6% of revenue, approximate), underpinning its pipeline and tech upgrades.
| Metric | Value (approx./reported) |
|---|---|
| 2024 Revenue | ≈ 6.5 billion CNY |
| Domestic revenue share | ≈ 90% |
| R&D spend | ≈ 6% of revenue |
| 2025 share repurchase | 0.67% of shares bought back for ≈300 million CNY |
| H-share / HKEX plan | June 2025: management authorized preparation for H-share listing in HK |
| Strategic alliances | Partnerships with Siemens, NVIDIA (tech & AI collaboration) |
- Industry standing: recognized as a China Outstanding Enterprise and National Advanced Enterprise in Refinement and Innovation, signaling government and industry endorsement.
- Capital allocation: the 2025 buyback (≈300M CNY, 0.67% stake) signals confidence in cash generation and EPS support.
- International expansion: H-share preparation (authorized June 2025) aims to broaden investor base and support cross-border M&A or licensing.
- Tech & pipeline leverage: alliances with Siemens and NVIDIA accelerate digitalization, smart manufacturing and AI-driven R&D, improving time-to-market and cost efficiency.
- Risk profile: heavy China concentration (~90% of revenue) constrains revenue diversification and exposes the company to domestic regulatory and reimbursement shifts.
Changchun High-Tech Industries (Group) Inc. (000661.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.